FDA Panel Backs Moderna mRNA Flu Vaccine For Older Adults
6d
Developing
2
FDA's Vaccines and Related Biological Products Advisory Committee unanimously recommended Moderna's mRNA seasonal flu vaccine, mFlusiva, for adults 50 and older on Thursday, June 18, 2026, advancing it toward possible FDA approval. NPR
